ArticleBMJ open respiratory research2020
Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey.
Article in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Prevalence of nontuberculous mycobacteria isolates and pulmonary disease from respiratory tract samples in persons investigated for presumed tuberculosis from three West African countries, an analysis of three prospective cohort studies.BMC infectious diseases · 2026Article
- 5-Substituted 4-Thiouridines, 4-Thio-2'-deoxyuridines and Their Oligoglycol Carbonate Prodrugs as Promising Antimicrobial Agents.International journal of molecular sciences · 2025Article
- Assessment of Healthcare Professionals' Knowledge Regarding Nontuberculosis Mycobacterial Infections at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia, 2024: A Cross-Sectional Study.Journal of clinical laboratory analysis · 2025Article
- Insights from the European Nontuberculous mycobacterial pulmonary disease PAtient Disease Experience (ENPADE) survey- exploring disease burden and impact.BMC pulmonary medicine · 2025Article
- Epidemiology of bronchiectasis at a single center in Japan: a retrospective cohort study.BMC pulmonary medicine · 2024Observational
- Patients at risk of nontuberculous mycobacterial pulmonary disease who need testing evaluated using a modified Delphi process by European experts.ERJ open research · 2024Article
- Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.Pharmacy (Basel, Switzerland) · 2024Review
- Global survey of physician testing practices for nontuberculous mycobacteria.ERJ open research · 2023Article
- The roles of neutrophils in non-tuberculous mycobacterial pulmonary disease.Annals of clinical microbiology and antimicrobials · 2023Review
- Case studies to illustrate good practice in the management of non-tuberculous mycobacterial pulmonary disease.Respiratory medicine case reports · 2022Article
- Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan.Frontiers in microbiology · 2022Article
- The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands.ERJ open research · 2021Article
- Computed Tomography in Adults with Bronchiectasis and Nontuberculous Mycobacterial Pulmonary Disease: Typical Imaging Findings.Journal of clinical medicine · 2021Article
- A novel DNA chromatography method to discriminate Mycobacterium abscessus subspecies and macrolide susceptibility.EBioMedicine · 2021Article
- European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights.ERJ open research · 2020Review
- Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis.Therapeutic advances in respiratory diseaseReview
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with bronchiectasis are at increased risk of developing non-tuberculous mycobacteria lung disease (NTM-LD), and published guidelines recommend regular testing for NTM infection in this patient population.
objectiveThis study aimed to survey physicians managing patients with bronchiectasis to understand the perceived risk of NTM to their patients, perceived disease severity and frequency of testing for NTM.
methodsThe study comprised an online survey of hospital-based physicians in the UK, Germany, Italy, France and the Netherlands. The target group were hospital-based physicians who had managed at least 10 adult patients with bronchiectasis over the preceding 12 months.
resultsIn total, 280 physicians completed the survey. Most (87%) thought their patients to be at particular risk of NTM, although it was perceived as a moderate risk versus other respiratory pathogens. Most perceived NTM-LD to impact patient morbidity (84%), and 61% indicated that NTM-LD significantly impacted mortality. 68% of all respondents did not test for NTM prior to initiating macrolide monotherapy, despite guidelines recommending testing. The perceived risk of and screening for NTM varied among countries.
conclusionsThe study demonstrates that physicians understand the risk of NTM-LD and associated morbidity in patients with bronchiectasis; however, a minority do not perceive that NTM-LD significantly affects mortality. Greater awareness of the need to test for NTM infection before initiating macrolide monotherapy for bronchiectasis is essential due to potential emergence of drug-resistant NTM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.